Human Pathology
Volume 38, Issue 2 , Pages 212-219, February 2007

Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma

  • Jean Jacques Michels, MD

      Affiliations

    • Department of Pathology, Centre François Baclesse, 14016 Caen Cedex 05, France
    • Corresponding Author InformationCorresponding author.
  • ,
  • Marnay Jacques, ScI

      Affiliations

    • Department of Pathology, Centre François Baclesse, 14016 Caen Cedex 05, France
  • ,
  • Michel Henry-Amar, MD

      Affiliations

    • Department of Clinical Research, Centre François Baclesse, 14016 Caen Cedex 05, France
  • ,
  • Stephane Bardet, MD

      Affiliations

    • Department of Nuclear Medicine, Centre François Baclesse, 14016 Caen Cedex 05, France

Received 26 June 2006; received in revised form 28 July 2006; accepted 4 August 2006. published online 13 November 2006.

Summary 

The aim of this study was to assess the prevalence, prognostic factors, and long-term outcome of tall cell variant (TCV) in comparison with the conventional forms of papillary thyroid carcinoma (PTC). A total of 945 patients with thyroid cancer were treated and followed up from 1960 to 1998. Pathologic review was performed in 778 patients (84%) of the cohort. Of these, 674 had PTC: 503 (74%) had conventional form (CF); 56 (8%), TCV; and 155 (17%), other variants of PTC. Tall cell variant was associated with tumors of larger size (P < .001), bilaterality (P < .02), multifocality (P < .04), and extrathyroidal invasion (P < .001). Treatment was similar in both groups, but neck dissection was performed more frequently in patients with TCV (P < .04). The 10-year overall and event-free survival rates were, respectively, 90% and 85% in the CF versus 79% and 67% in the TCV group (P < .001). Histologic subtype did not have an effect on clinical outcome after multivariate analysis, the most relevant factors being age, involved nodes, or the “Metastasis, Age, Completeness, Invasion, Size” classification after multivariate analysis. In this large cohort of patients, TCV represents 8.3% of PTC, and it is a more aggressive form of PTC than CF because of the higher stage and increased grade.

Keywords: Thyroid, Papillary carcinoma, Tall cell, Columnar cell, Prognosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0046-8177(06)00497-7

doi:10.1016/j.humpath.2006.08.001

Human Pathology
Volume 38, Issue 2 , Pages 212-219, February 2007